Connect
MJA
MJA

Iron deficiency and new insights into therapy

Michael SY Low and George Grigoriadis
Med J Aust 2017; 207 (2): 81-87. || doi: 10.5694/mja16.01304

Summary

 

  • Iron deficiency and iron deficiency anaemia remain prevalent in Australia.
  • The groups at highest risk are pre-menopausal women, socially disadvantaged people and those of Indigenous background.
  • Diagnosing iron deficiency using a full blood examination and iron studies can be difficult and can be further complicated by concomitant inflammation. Results of iron studies should always be interpreted as an overall picture rather than focusing on individual parameters. In difficult clinical scenarios, soluble transferrin receptor assays can be useful.
  • Management of iron deficiency involves identification and treatment of the cause of iron deficiency, as well as effective iron replacement.
  • Clinicians should always take a detailed history and perform a comprehensive physical examination of a patient with iron deficiency. Patients should be monitored even if a likely cause of iron deficiency is identified.
  • Patients who fail to respond to iron replacement or maintain iron status should be referred for further investigation, including endoscopy to exclude internal bleeding.
  • Both enteral and parenteral iron are effective at replacing iron. For most adult patients, we recommend trialling daily oral iron (30–100 mg of elemental iron) as the first-line therapy.
  • Safety and efficacy of intravenous iron infusions have improved with the availability of a newer formulation, ferric carboxymaltose. Patients who fail to respond to oral iron replacement can be safely managed with intravenous iron.
  • Blood transfusion for iron deficiency anaemia should be reserved for life-threatening situations and should always be followed by appropriate iron replacement.

 

  • Michael SY Low1,2
  • George Grigoriadis1,3

  • 1 Monash Health, Melbourne, VIC
  • 2 Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC
  • 3 Monash University, Melbourne, VIC


Acknowledgements: 

Michael Low is employed by Monash Health and funded by a Royal Australasian College of Physicians (RACP) National Health and Medical Research Council (NHMRC) CRB Blackburn Scholarship. George Grigoriadis is employed by Monash Health and Alfred Health and funded by a Victorian Cancer Agency Clinical Research Fellowship. We thank Shahla Vilcassim (Monash Haematology) for her help in attaining the figure in .

Competing interests:

No relevant disclosures.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.